Under pathological conditions including hypoxia and metabolic disorders, dysregulated ERO1α expression is closely related to the occurrence and development of various diseases such as cancer (Chen et al., 2024), neurodegenerative diseases (Lehtonen et al., 2016), cardiovascular disorders (Jha et al., 2023), diabetes (Wright et al., 2013), and inflammatory conditions (Ranchoux et al., 2015). Here, ERO1A is linked to cardiovascular disorder.